Having trouble accessing articles? Reset your cache.

MNCs gain ground in China’s centralized procurement

Five multinational originator companies were among the winning bidders in China’s national expansion of its centralized procurement program for generic and off-patent drugs in a process that saw steep price cuts and more robust participation by Western companies compared with last year’s pilot.

The list of winning bidders released by China’s Joint Procurement Office on Wednesday also marked the entrance of global generics companies, including the first winning bid by an Indian company.

Under the

Read the full 732 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers